TITLE

123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease

AUTHOR(S)
Orimo, S.; Ozawa, E.; Nakade, S.; Sugimoto, T.; H Mizusawa
PUB. DATE
August 1999
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Aug1999, p189
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66877517

 

Related Articles

  • Cardiac ¹²³I-MIBG scintigraphy in patients with drug induced parkinsonism. Lee, P. H.; Kim, J. S.; Shin, D. H.; Yoon, S-N; Huh, K. // Journal of Neurology, Neurosurgery & Psychiatry;Mar2006, Vol. 77 Issue 3, p372 

    Cardiac sympathetic dysfunction was investigated using 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy in 20 patients with drug induced parkinsonism (DIP). The mean heart to mediastinum ratio was significantly greater in patients with DIP than in those with Parkinson's disease (mean...

  • Nonmotor Symptoms in Patients with PARK2 Mutations. Yoritaka, Asako; Shimo, Yumi; Shimo, Yasushi; Inoue, Yuichi; Yoshino, Hiroyo; Hattori, Nobutaka // Parkinson's Disease (20420080);2011, p1 

    Decreased 123I-meta-iodobenzylguanidine (MIBG) uptake in MIBG myocardial scintigraphy, olfactory dysfunction, and rapid eye movement (REM) sleep behavior disorder (RBD) are considered useful early indicators of Parkinson disease. We investigated whether patients with PARK2 mutations exhibited...

  • MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Treglia, Giorgio; Cason, Ernesto; Stefanelli, Antonella; Cocciolillo, Fabrizio; Di Giuda, Daniela; Fagioli, Giorgio; Giordano, Alessandro // Clinical Autonomic Research;Feb2012, Vol. 22 Issue 1, p43 

    Objective: Differential diagnosis between Parkinson's disease (PD) and other Parkinsonism using clinical criteria or imaging methods is often difficult. The purpose of this study is to systematically review and meta-analyze published data about the diagnostic performance of myocardial...

  • Idiopathic REM Sleep Behavior Disorder: Implications for the Pathogenesis of Lewy Body Diseases. Miyamoto, Tomoyuki; Miyamoto, Masayuki; Iwanami, Masaoki; Hirata, Koichi // Parkinson's Disease (20420080);2011, p1 

    Objectives. Both results of the odor identification and cardiac 123I-metaiodobenzylguanidine accumulation have been investigated for their potential to enhance the detection of pathogenesis resembling that of Lewy body-related α-synucleinopathies in patients clinically diagnosed as having...

  • Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease. Shimizu, Soichiro; Hirao, Kentaro; Kanetaka, Hidekazu; Namioka, Nayuta; Hatanaka, Hirokuni; Hirose, Daisuke; Fukasawa, Raita; Umahara, Takahiko; Sakurai, Hirohumi; Hanyu, Haruo // European Journal of Nuclear Medicine & Molecular Imaging;Jan2016, Vol. 43 Issue 1, p184 

    Purpose: I-2β-Carbomethoxy-3β-(4-iodophenyl)- N-(3-fluoropropyl) nortropane (I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT SPECT) and I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy can be used to assist in the diagnosis of patients with dementia...

  • Diagnostic and Pathophysiological Impact of MyocardialMIBG Scintigraphy in Parkinson's Disease. Spiegel, Jörg // Parkinson's Disease (20420080);2011, p1 

    Myocardial MIBG scintigraphy is established in the diagnosis and differential diagnosis of Parkinson's disease (PD). Numerous studies address the pathophysiological impact of myocardial MIBG scintigraphy: the myocardial MIBG uptake correlates with the clinical phenotype of PD; the background of...

  • Diagnostic and Pathophysiological Impact of Myocardial MIBG Scintigraphy in Parkinson's Disease. Spiegel, Jörg // Parkinson's Disease (20420080);2010, p1 

    Myocardial MIBG scintigraphy is established in the diagnosis and differential diagnosis of Parkinson's disease (PD). Numerous studies address the pathophysiological impact of myocardial MIBG scintigraphy: the myocardial MIBG uptake correlates with the clinical phenotype of PD; the background of...

  • Neurodegenerative Disorders. Bain, Peter; Blass, John; Jenkins, Harri; Johnson, Michael // Current Medical Literature: Neurology;2011, Vol. 27 Issue 4, p121 

    The article comments on studies on neurodegenerative disorders. It is discussed that I-metaiodobenzylguanidine (I-MIBG) cardiac scintigraphy assists on the diagnosis and distinction among Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Alzheimer's Disease (AD). A study explained...

  • Neuronal imaging using SPECT. Yamashina, Shohei; Yamazaki, Jun-Ichi // European Journal of Nuclear Medicine & Molecular Imaging;Jul2007 Supplement, Vol. 34, p62 

    123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy is one of only a few methods available for objective evaluation of cardiac sympathetic function at the clinical level. Disorders of cardiac sympathetic function play an important role in various heart diseases, and MIBG provides an...

  • Recent developments in innervation imaging using iodine-123-metaiodobenzylguanidine scintigraphy in Lewy body diseases. Treglia, Giorgio; Cason, Ernesto; Gabellini, Anna; Giordano, Alessandro; Fagioli, Giorgio // Neurological Sciences;Aug2010, Vol. 31 Issue 4, p417 

    Radiolabeled metaiodobenzylguanidine (MIBG) is an analog of guanethidine and is taken up by the postganglionic presynaptic nerve endings. MIBG uptake in the heart correlates with adrenergic function, which can be reduced in Lewy body diseases. We described the recent developments in innervation...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics